A new study published in the European Journal of Medical Research revealed that dapagliflozin, a sodium-glucose ...

Amgen AMGN reported second-quarter 2025 adjusted earnings of $6.02 per share, which beat the Zacks Consensus Estimate of ...

CRD-750 is the first clinical-stage PDE9 inhibitor to be evaluated in patients in both types of chronic heart failure The CYCLE-1-REF trial is evaluating patients with heart failure with reduced ...